Headlines about Tyme Technologies (NASDAQ:TYME) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tyme Technologies earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.3950797306982 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

Several research analysts have issued reports on TYME shares. Evercore ISI started coverage on Tyme Technologies in a research report on Friday, November 17th. They issued an “outperform” rating and a $7.00 target price on the stock. HC Wainwright started coverage on Tyme Technologies in a research report on Friday, December 15th. They issued a “buy” rating and a $8.00 target price on the stock. Canaccord Genuity started coverage on Tyme Technologies in a research report on Wednesday, January 3rd. They issued a “buy” rating on the stock. Finally, BidaskClub cut Tyme Technologies from a “hold” rating to a “sell” rating in a research report on Friday, January 26th.

Shares of Tyme Technologies (TYME) traded down $0.10 during trading hours on Friday, reaching $3.99. The company’s stock had a trading volume of 88,321 shares, compared to its average volume of 188,424. The stock has a market capitalization of $362.70, a PE ratio of -23.47 and a beta of -0.59. Tyme Technologies has a fifty-two week low of $2.14 and a fifty-two week high of $9.50.

In other Tyme Technologies news, COO Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $3.34, for a total value of $167,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/tyme-technologies-tyme-earns-daily-news-impact-score-of-0-12/1860013.html.

Tyme Technologies Company Profile

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.